# AI Medical Service

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ai-medical-service

- Industry: Software
- Headquarters: Tokyo, Japan
- Website: www.ai-ms.com
- Total disclosed funding: $114M
- Latest round: Series C (Apr 26, 2022)
- Investors on record: 12

## About

Based in Japan, AI Medical Service Inc. specializes in developing innovative AI-driven software solutions for gastrointestinal cancer diagnostics, enhancing the accuracy and efficiency of endoscopic examinations.AI Medical Service Inc., founded in 2017 in Tokyo, Japan, focuses on advancing gastrointestinal cancer diagnostics through artificial intelligence. The company has successfully completed a total of 3 deals, with its most recent funding round being a Series C raise of JPY 8 billion on April 26, 2022, led by SB Investment Advisers, alongside investors like Globis Capital Partners, World Innovation Lab, and Incubate Fund. The total amount raised by the company is JPY 8 billion, resulting in a current valuation of JPY 42,575.662 million.AI Medical Service Inc. focuses on developing advanced AI-driven software solutions for gastrointestinal (GI) cancer diagnostics. Their flagship products include gastroAI™ model-G2, which assists in detecting early gastric cancer and adenomas during endoscopic examinations, and gastroAI™ model-EIRL, which supports the diagnosis of colorectal polyps. Additionally, the company offers gastroBASE screening, a web-based service that facilitates the sharing of endoscopic examination data and secondary readings, thereby optimizing workflow efficiencies in gastric cancer screening. These products are designed to enhance diagnostic accuracy and early cancer detection, addressing critical healthcare needs globally. The primary customers of these solutions include hospitals, clinics, and healthcare providers operating in regions such as North America, Europe, and select markets in Asia, where the demand for early cancer detection and diagnostic support is significant.In the most recent financial year, 2019, AI Medical Service Inc. reported a revenue of JPY 354,330.In April 2022, AI Medical Service Inc. raised JPY 8 billion in Series C funding, led by SB Investment Advisers, to enhance the global adoption of endoscopic AI and develop an in-house cloud-based platform. The company plans to launch new AI-driven products aimed at improving diagnostics within the next two years, targeting expansion into key markets in North America and Europe by 2024.

## Funding rounds

- Series C, Apr 26, 2022, $62M — Globis Capital Partners, Incubate Fund, World Innovation Lab, SB Investment Advisers
- Series B, Oct 4, 2019, $43M — Daiwa Corporate Investment, Globis Capital Partners, SMBC Venture Capital, SPARX Group, Ryoyo Electro Corporation, World Innovation Lab, Sony Innovation Fund, Aflac Corporate Ventures, Japan Post Capital, Japan Lifeline Co.,Ltd.
- Series A, Aug 10, 2018, $9M — Incubate Fund

## Investors

- Incubate Fund (https://capitalatlas.ai/funds/incubate-fund) — Series A, Series C
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series B
- Globis Capital Partners (https://capitalatlas.ai/funds/globis-capital-partners) — Series B, Series C
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B
- SPARX Group (https://capitalatlas.ai/funds/sparx-group) — Series B
- Ryoyo Electro Corporation — Series B
- World Innovation Lab — Series B, Series C
- Sony Innovation Fund (https://capitalatlas.ai/funds/sony-innovation-fund) — Series B
- Aflac Corporate Ventures (https://capitalatlas.ai/funds/aflac-corporate-ventures) — Series B
- Japan Post Capital (https://capitalatlas.ai/funds/japan-post-capital) — Series B
- Japan Lifeline Co.,Ltd. — Series B
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series C